Completed PHASE3 INTERVENTIONAL NCT00129142

Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy

A Randomized, Double Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy

Sponsor: GTx

Conditions Fractures Osteoporosis Prostate Cancer

Interventions Toremifene Citrate

Updated 6 times since 2017 Last updated: Nov 13, 2013 Started: Oct 31, 2003 Primary completion: Nov 30, 2007 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Fractures and Osteoporosis, this trial is completed. The trial is conducted by GTx and has accumulated 6 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Data source: GTx

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albany, United States , Albuquerque, United States , Alexandria, United States , Allentown, United States , Anaheim, United States , Ann Arbor, United States , Annapolis, United States , Asheboro, United States , Atlanta, United States and 113 more locations